{"id":834379,"date":"2025-04-07T08:05:08","date_gmt":"2025-04-07T12:05:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/"},"modified":"2025-04-07T08:05:08","modified_gmt":"2025-04-07T12:05:08","slug":"myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/","title":{"rendered":"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SALT LAKE CITY, April  07, 2025  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LMMPaGodvamlKE3RkjSw52tfVsgv2SlgF_ZSTUiqoyut-pkYUNA_DUCHrR7aTrC6hPTKrozXP0vZj48kM_6WVrGnvopW9fcXrR3yFuKp1LI=\" rel=\"nofollow\" target=\"_blank\">Myriad Genetics, Inc<\/a>. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025.<\/p>\n<p>A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&amp;Ls, and driving growth through innovative go-to-market strategies.<\/p>\n<p>\u201cBrian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,\u201d said Sam Raha, incoming president and CEO of Myriad Genetics. \u201cHe will be a critical member of our leadership team and will play an instrumental role in scaling our business, accelerating product adoption, and driving sustained profitable growth.\u201d<\/p>\n<p>&#8220;I\u2019m thrilled to join Myriad Genetics, which has such a deep commitment to advancing genetic insights and plays a critical role in empowering patients, physicians, and partners with the information needed to improve health outcomes,\u201d said Donnelly. \u201cI look forward to working alongside this talented team to expand our impact, foster innovation, and accelerate the company\u2019s growth while staying true to Myriad\u2019s mission of advancing health and well-being for all.&#8221;<\/p>\n<p>Prior to joining Myriad Genetics, Donnelly held senior commercial and general management roles at leading organizations such as Ancestry, Amazon, and Illumina, successfully driving business growth across global markets and product lines. His ability to align commercial efforts with organizational goals, enhance brand positioning, and deliver shareholder value makes him well-positioned to build on Myriad\u2019s mission.<\/p>\n<p>\n        <strong>About Myriad Genetics<\/strong><br \/>\n        <br \/>Myriad Genetics is a leading molecular diagnostics testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xzbEcI8v5NXtERNSiOJ7ATFq5OKi_Kg6KXuhojcEYZzjizzNXyUOPSVjdVh59vXxF14teGlDim7CikBk7bByZg==\" rel=\"nofollow\" target=\"_blank\">www.myriad.com<\/a>.<\/p>\n<p>\n        <strong>Safe Harbor Statement\u00a0 \u00a0<\/strong><br \/>\n        <br \/>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act of 1995, including that Mr. Donnelly will be a critical member of the company\u2019s leadership team and will play an instrumental role in scaling the company\u2019s business, accelerating product adoption, and driving sustained profitable growth. These \u201cforward-looking statements\u201d are management\u2019s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company\u2019s filings with the U.S. Securities and Exchange Commission, including the company\u2019s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company\u2019s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.\u00a0<\/p>\n<p>\n        <strong>Investor Contact\u00a0<\/strong><br \/>\n        <br \/>Matt Scalo\u00a0<br \/>(801) 584-3532\u00a0<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9vN4wVDxf6r-S0kVRx_JOdCMztNiT0AvfROHfixlt8i36qzRu3YAXsjVW9zGhg3PcyrVIgLpdW7MSVyCVIwkAA==\" rel=\"nofollow\" target=\"_blank\"><u>IR@myriad.com<\/u><\/a>\u00a0<\/p>\n<p>\n        <strong>Media Contact\u00a0<\/strong><br \/>\n        <br \/>Kate Schraml<br \/>(224) 875-4493<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=7UoTONwd5E4lqAgQY7eavRfulcL8YI70ss-EeVP7vHo9IA5GUvw3NGFPiq1aaTZMVVtoReT3-xodCa0B8tAaBg==\" rel=\"nofollow\" target=\"_blank\"><u>PR@myriad.com<\/u><\/a>\u00a0\u00a0<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YjEyMjlmNGEtMWZhMy00MGI3LWEwOWMtZmEzYmMzNjc0NzkwLTEwMTk0NjAtMjAyNS0wNC0wNy1lbg==\/tiny\/Myriad-Genetics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&amp;Ls, and driving growth through innovative go-to-market strategies. \u201cBrian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,\u201d said Sam Raha, incoming president and CEO of Myriad Genetics. \u201cHe will be a critical member of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-834379","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&amp;Ls, and driving growth through innovative go-to-market strategies. \u201cBrian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,\u201d said Sam Raha, incoming president and CEO of Myriad Genetics. \u201cHe will be a critical member of &hellip; Continue reading &quot;Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T12:05:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer\",\"datePublished\":\"2025-04-07T12:05:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/\"},\"wordCount\":552,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/\",\"name\":\"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=\",\"datePublished\":\"2025-04-07T12:05:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/","og_locale":"en_US","og_type":"article","og_title":"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - Market Newsdesk","og_description":"SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) &#8212; Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&amp;Ls, and driving growth through innovative go-to-market strategies. \u201cBrian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric solutions and a strong focus on commercial execution,\u201d said Sam Raha, incoming president and CEO of Myriad Genetics. \u201cHe will be a critical member of &hellip; Continue reading \"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-07T12:05:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer","datePublished":"2025-04-07T12:05:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/"},"wordCount":552,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/","name":"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=","datePublished":"2025-04-07T12:05:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQxNzI1NCM2ODUxODU1IzIwMDc4ODc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/myriad-genetics-names-brian-donnelly-as-new-chief-commercial-officer\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834379","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=834379"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/834379\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=834379"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=834379"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=834379"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}